A Dose-Response Strategy Reveals Differences between Normal-Weight and Obese Men in Their Metabolic and Inflammatory Responses to a High-Fat Meal.

A dose-response strategy may not only allow investigation of the impact of foods and nutrients on human health but may also reveal differences in the response of individuals to food ingestion based on their metabolic health status. In a randomized crossover study, we challenged 19 normal-weight (BMI: 20-25 kg/m(2)) and 18 obese (BMI: >30 kg/m(2)) men with 500, 1000, and 1500 kcal of a high-fat (HF) meal (60.5% energy from fat). Blood was taken at baseline and up to 6 h postprandially and analyzed for a range of metabolic, inflammatory, and hormonal variables, including plasma glucose, lipids, and C-reactive protein and serum insulin, glucagon-like peptide-1, interleukin-6 (IL-6), and endotoxin. Insulin was the only variable that could differentiate the postprandial response of normal-weight and obese participants at each of the 3 caloric doses. A significant response of the inflammatory marker IL-6 was only observed in the obese group after ingestion of the HF meal containing 1500 kcal [net incremental AUC (iAUC) = 22.9 ± 6.8 pg/mL × 6 h, P = 0.002]. Furthermore, the net iAUC for triglycerides significantly increased from the 1000 to the 1500 kcal meal in the obese group (5.0 ± 0.5 mmol/L × 6 h vs. 6.0 ± 0.5 mmol/L × 6 h; P = 0.015) but not in the normal-weight group (4.3 ± 0.5 mmol/L × 6 h vs. 4.8 ± 0.5 mmol/L × 6 h; P = 0.31). We propose that caloric dose-response studies may contribute to a better understanding of the metabolic impact of food on the human organism. This study was registered at clinicaltrials.gov as NCT01446068.

Stimulus-response curve of human motor nerves: multicenter assessment of various indexes.

The value of various indexes to characterize the stimulus-response curve of human motor nerves was assessed in 40 healthy subjects recruited from four European centers of investigation (Créteil, Lausanne, Liège, Marseille). Stimulus-response curves were established by stimulating the right median and ulnar motor nerves at the wrist, with stimulus durations of 0.05 and 0.5 ms. The following parameters were studied: the threshold intensity of stimulation to obtain 10% (I 10), 50% (I 50), and 90% (I 90) of the maximal compound muscle action potential, the ratios I 10/I 50, I 90/I 50, (I 90 - I 10)/I 10, (I 90-I 50)/I 50, and (I 50 - I 10)/I 10, and the slopes of the stimulus-response curves with or without normalization to I 50. For each parameter, within-center variability and reproducibility (in a test-retest study) were assessed and between-center comparisons were made. For most of the parameters, the results varied significantly within and between the centers. Within the centers, only the ratios I 10/I 50 and I 90/I 50 were found constant and reproducible. Between the centers, the absolute intensity thresholds (I 10, I 50, I 90) and the ratio I 90/I 50 did not show significant differences at stimulus duration of 0.5 ms, whatever the stimulated nerve. The reduced variability and good reproducibility of the ratios I 10/I 50 and I 90/I 50 open perspectives in neurophysiological practice for the use of these indexes of the stimulus-response curve, a rapid and noninvasive test.

Do peroxisome proliferating compounds pose a hepatocarcinogenic hazard to humans?

The purpose of the workshop "Do Peroxisome Proliferating Compounds Pose a Hepatocarcinogenic Hazard to Humans?" was to provide a review of the current state of the science on the relationship between peroxisome proliferation and hepatocarcinogenesis. There has been much debate regarding the mechanism by which peroxisome proliferators may induce liver tumors in rats and mice and whether these events occur in humans. A primary goal of the workshop was to determine where consensus might be reached regarding the interpretation of these data relative to the assessment of potential human risks. A core set of biochemical and cellular events has been identified in the rodent strains that are susceptible to the hepatocarcinogenic effects of peroxisome proliferators, including peroxisome proliferation, increases in fatty acyl-CoA oxidase levels, microsomal fatty acid oxidation, excess production of hydrogen peroxide, increases in rates of cell proliferation, and expression and activation of the alpha subtype of the peroxisome proliferator-activated receptor (PPAR-alpha). Such effects have not been identified clinically in liver biopsies from humans exposed to peroxisome proliferators or in in vitro studies with human hepatocytes, although PPAR-alpha is expressed at a very low level in human liver. Consensus was reached regarding the significant intermediary roles of cell proliferation and PPAR-alpha receptor expression and activation in tumor formation. Information considered necessary for characterizing a compound as a peroxisome proliferating hepatocarcinogen include hepatomegaly, enhanced cell proliferation, and an increase in hepatic acyl-CoA oxidase and/or palmitoyl-CoA oxidation levels. Given the lack of genotoxic potential of most peroxisome proliferating agents, and since humans appear likely to be refractive or insensitive to the tumorigenic response, risk assessments based on tumor data may not be appropriate. However, nontumor data on intermediate endpoints would provide appropriate toxicological endpoints to determine a point of departure such as the LED10 or NOAEL which would be the basis for a margin-of-exposure (MOE) risk assessment approach. Pertinent factors to be considered in the MOE evaluation would include the slope of the dose-response curve at the point of departure, the background exposure levels, and variability in the human response.

Desensitization and phosphorylation of the glucagon-like peptide-1 (GLP-1) receptor by GLP-1 and 4-phorbol 12-myristate 13-acetate.

Glucagon-like peptide-1 (GLP-1) stimulates glucose-induced insulin secretion by binding to a specific G protein-coupled receptor linked to activation of the adenylyl cyclase pathway. Here, using insulinoma cell lines, we studied homologous and heterologous desensitization of GLP-1-induced cAMP production. Preexposure of the cells to GLP-1 induced a decrease in GLP-1-mediated cAMP production, as assessed by a 3- to 5-fold rightward shift of the dose-response curve and an approximately 20 percent decrease in the maximal production of cAMP. Activation of protein kinase C by the phorbol ester phorbol 12-myristate 13-acetate (PMA) also induced desensitization of the GLP-1-mediated response, leading to a 6- to 9-fold shift in the EC50 and a 30% decrease in the maximal production of cAMP. Both forms of desensitization were additive, and the protein kinase C inhibitor RO-318220 inhibited PMA-induced desensitization, but not agonist-induced desensitization. GLP-1- and PMA-dependent desensitization correlated with receptor phosphorylation, and the levels of phosphorylation induced by the two agents were additive. Furthermore, PMA-induced, but not GLP-1-induced, phosphorylation was totally inhibited by RO-318220. Internalization of the GLP-1 receptor did not participate in the desensitization induced by PMA, as a mutant GLP-1 receptor lacking the last 20 amino acids of the cytoplasmic tail was found to be totally resistant to the internalization process, but was still desensitized after PMA preexposure. PMA and GLP-1 were not able to induce the phosphorylation of a receptor deletion mutant lacking the last 33 amino acids of the cytoplasmic tail, indicating that the phosphorylation sites were located within the deleted region. The cAMP production mediated by this deletion mutant was not desensitized by PMA and was only poorly desensitized by GLP-1. Together, our results indicate that the production of cAMP and, hence, the stimulation of insulin secretion induced by GLP-1 can be negatively modulated by homologous and heterologous desensitization, mechanisms that involve receptor phosphorylation.

Inducing effect of skeletal muscle extracts on the appearance of calbindin-immunoreactive dorsal root ganglion cells in culture.

Calbindin D-28k is a calcium-binding protein which is not expressed by dorsal root ganglion cells cultured from 6-day-old (E6) chick embryos. When soluble muscle extracts from embryos at E11, E18 or chickens 2 weeks after hatching were added immediately after seeding, dorsal root ganglia cells grown at E6 displayed neuronal subpopulations expressing calbindin immunoreactivity with time; the effect of muscle extract on the percentage of calbindin-immunoreactive dorsal root ganglia cells followed a dose-response curve. When muscle extract was added to cultures after a 3 day delay, the percentage of calbindin-expressing neurons was unchanged. The effect produced by muscle extract and, to a lesser degree, skin extract on the appearance of calbindin-positive neurons was not reproduced by brain or liver extracts while all four exerted a trophic action on cultured neurons. Hence it is assumed that muscle extract contains a factor which produces an inductive effect on the initiation of calbindin-expression by uncommitted subpopulations of sensory neurons rather than a trophic influence on the selective survival of covertly committed neuronal subpopulations. The fact that muscle extract promoted calbindin expression by dorsal root ganglia cells in neuron-enriched as well as in mixed dorsal root ganglion cell cultures indicates that the factor would act directly on sensory neurons rather than indirectly through mediation of non-neuronal cells. Since the active muscular factor was non-dialysable, heat-inactivated, trypsin-sensitive and retained by molecular filters with a cut-off of 30 K, this factor is probably a protein.

Reliability of methods used for the risk assessment of mixture of micropollutants in aquatic enviromments : from theoretical concepts to field observations

Ces dernières années, de nombreuses recherches ont mis en évidence les effets toxiques des micropolluants organiques pour les espèces de nos lacs et rivières. Cependant, la plupart de ces études se sont focalisées sur la toxicité des substances individuelles, alors que les organismes sont exposés tous les jours à des milliers de substances en mélange. Or les effets de ces cocktails ne sont pas négligeables. Cette thèse de doctorat s'est ainsi intéressée aux modèles permettant de prédire le risque environnemental de ces cocktails pour le milieu aquatique. Le principal objectif a été d'évaluer le risque écologique des mélanges de substances chimiques mesurées dans le Léman, mais aussi d'apporter un regard critique sur les méthodologies utilisées afin de proposer certaines adaptations pour une meilleure estimation du risque. Dans la première partie de ce travail, le risque des mélanges de pesticides et médicaments pour le Rhône et pour le Léman a été établi en utilisant des approches envisagées notamment dans la législation européenne. Il s'agit d'approches de « screening », c'est-à-dire permettant une évaluation générale du risque des mélanges. Une telle approche permet de mettre en évidence les substances les plus problématiques, c'est-à-dire contribuant le plus à la toxicité du mélange. Dans notre cas, il s'agit essentiellement de 4 pesticides. L'étude met également en évidence que toutes les substances, même en trace infime, contribuent à l'effet du mélange. Cette constatation a des implications en terme de gestion de l'environnement. En effet, ceci implique qu'il faut réduire toutes les sources de polluants, et pas seulement les plus problématiques. Mais l'approche proposée présente également un biais important au niveau conceptuel, ce qui rend son utilisation discutable, en dehors d'un screening, et nécessiterait une adaptation au niveau des facteurs de sécurité employés. Dans une deuxième partie, l'étude s'est portée sur l'utilisation des modèles de mélanges dans le calcul de risque environnemental. En effet, les modèles de mélanges ont été développés et validés espèce par espèce, et non pour une évaluation sur l'écosystème en entier. Leur utilisation devrait donc passer par un calcul par espèce, ce qui est rarement fait dû au manque de données écotoxicologiques à disposition. Le but a été donc de comparer, avec des valeurs générées aléatoirement, le calcul de risque effectué selon une méthode rigoureuse, espèce par espèce, avec celui effectué classiquement où les modèles sont appliqués sur l'ensemble de la communauté sans tenir compte des variations inter-espèces. Les résultats sont dans la majorité des cas similaires, ce qui valide l'approche utilisée traditionnellement. En revanche, ce travail a permis de déterminer certains cas où l'application classique peut conduire à une sous- ou sur-estimation du risque. Enfin, une dernière partie de cette thèse s'est intéressée à l'influence que les cocktails de micropolluants ont pu avoir sur les communautés in situ. Pour ce faire, une approche en deux temps a été adoptée. Tout d'abord la toxicité de quatorze herbicides détectés dans le Léman a été déterminée. Sur la période étudiée, de 2004 à 2009, cette toxicité due aux herbicides a diminué, passant de 4% d'espèces affectées à moins de 1%. Ensuite, la question était de savoir si cette diminution de toxicité avait un impact sur le développement de certaines espèces au sein de la communauté des algues. Pour ce faire, l'utilisation statistique a permis d'isoler d'autres facteurs pouvant avoir une influence sur la flore, comme la température de l'eau ou la présence de phosphates, et ainsi de constater quelles espèces se sont révélées avoir été influencées, positivement ou négativement, par la diminution de la toxicité dans le lac au fil du temps. Fait intéressant, une partie d'entre-elles avait déjà montré des comportements similaires dans des études en mésocosmes. En conclusion, ce travail montre qu'il existe des modèles robustes pour prédire le risque des mélanges de micropolluants sur les espèces aquatiques, et qu'ils peuvent être utilisés pour expliquer le rôle des substances dans le fonctionnement des écosystèmes. Toutefois, ces modèles ont bien sûr des limites et des hypothèses sous-jacentes qu'il est important de considérer lors de leur application. - Depuis plusieurs années, les risques que posent les micropolluants organiques pour le milieu aquatique préoccupent grandement les scientifiques ainsi que notre société. En effet, de nombreuses recherches ont mis en évidence les effets toxiques que peuvent avoir ces substances chimiques sur les espèces de nos lacs et rivières, quand elles se retrouvent exposées à des concentrations aiguës ou chroniques. Cependant, la plupart de ces études se sont focalisées sur la toxicité des substances individuelles, c'est à dire considérées séparément. Actuellement, il en est de même dans les procédures de régulation européennes, concernant la partie évaluation du risque pour l'environnement d'une substance. Or, les organismes sont exposés tous les jours à des milliers de substances en mélange, et les effets de ces "cocktails" ne sont pas négligeables. L'évaluation du risque écologique que pose ces mélanges de substances doit donc être abordé par de la manière la plus appropriée et la plus fiable possible. Dans la première partie de cette thèse, nous nous sommes intéressés aux méthodes actuellement envisagées à être intégrées dans les législations européennes pour l'évaluation du risque des mélanges pour le milieu aquatique. Ces méthodes sont basées sur le modèle d'addition des concentrations, avec l'utilisation des valeurs de concentrations des substances estimées sans effet dans le milieu (PNEC), ou à partir des valeurs des concentrations d'effet (CE50) sur certaines espèces d'un niveau trophique avec la prise en compte de facteurs de sécurité. Nous avons appliqué ces méthodes à deux cas spécifiques, le lac Léman et le Rhône situés en Suisse, et discuté les résultats de ces applications. Ces premières étapes d'évaluation ont montré que le risque des mélanges pour ces cas d'étude atteint rapidement une valeur au dessus d'un seuil critique. Cette valeur atteinte est généralement due à deux ou trois substances principales. Les procédures proposées permettent donc d'identifier les substances les plus problématiques pour lesquelles des mesures de gestion, telles que la réduction de leur entrée dans le milieu aquatique, devraient être envisagées. Cependant, nous avons également constaté que le niveau de risque associé à ces mélanges de substances n'est pas négligeable, même sans tenir compte de ces substances principales. En effet, l'accumulation des substances, même en traces infimes, atteint un seuil critique, ce qui devient plus difficile en terme de gestion du risque. En outre, nous avons souligné un manque de fiabilité dans ces procédures, qui peuvent conduire à des résultats contradictoires en terme de risque. Ceci est lié à l'incompatibilité des facteurs de sécurité utilisés dans les différentes méthodes. Dans la deuxième partie de la thèse, nous avons étudié la fiabilité de méthodes plus avancées dans la prédiction de l'effet des mélanges pour les communautés évoluant dans le système aquatique. Ces méthodes reposent sur le modèle d'addition des concentrations (CA) ou d'addition des réponses (RA) appliqués sur les courbes de distribution de la sensibilité des espèces (SSD) aux substances. En effet, les modèles de mélanges ont été développés et validés pour être appliqués espèce par espèce, et non pas sur plusieurs espèces agrégées simultanément dans les courbes SSD. Nous avons ainsi proposé une procédure plus rigoureuse, pour l'évaluation du risque d'un mélange, qui serait d'appliquer d'abord les modèles CA ou RA à chaque espèce séparément, et, dans une deuxième étape, combiner les résultats afin d'établir une courbe SSD du mélange. Malheureusement, cette méthode n'est pas applicable dans la plupart des cas, car elle nécessite trop de données généralement indisponibles. Par conséquent, nous avons comparé, avec des valeurs générées aléatoirement, le calcul de risque effectué selon cette méthode plus rigoureuse, avec celle effectuée traditionnellement, afin de caractériser la robustesse de cette approche qui consiste à appliquer les modèles de mélange sur les courbes SSD. Nos résultats ont montré que l'utilisation de CA directement sur les SSDs peut conduire à une sous-estimation de la concentration du mélange affectant 5 % ou 50% des espèces, en particulier lorsque les substances présentent un grand écart- type dans leur distribution de la sensibilité des espèces. L'application du modèle RA peut quant à lui conduire à une sur- ou sous-estimations, principalement en fonction de la pente des courbes dose- réponse de chaque espèce composant les SSDs. La sous-estimation avec RA devient potentiellement importante lorsque le rapport entre la EC50 et la EC10 de la courbe dose-réponse des espèces est plus petit que 100. Toutefois, la plupart des substances, selon des cas réels, présentent des données d' écotoxicité qui font que le risque du mélange calculé par la méthode des modèles appliqués directement sur les SSDs reste cohérent et surestimerait plutôt légèrement le risque. Ces résultats valident ainsi l'approche utilisée traditionnellement. Néanmoins, il faut garder à l'esprit cette source d'erreur lorsqu'on procède à une évaluation du risque d'un mélange avec cette méthode traditionnelle, en particulier quand les SSD présentent une distribution des données en dehors des limites déterminées dans cette étude. Enfin, dans la dernière partie de cette thèse, nous avons confronté des prédictions de l'effet de mélange avec des changements biologiques observés dans l'environnement. Dans cette étude, nous avons utilisé des données venant d'un suivi à long terme d'un grand lac européen, le lac Léman, ce qui offrait la possibilité d'évaluer dans quelle mesure la prédiction de la toxicité des mélanges d'herbicide expliquait les changements dans la composition de la communauté phytoplanctonique. Ceci à côté d'autres paramètres classiques de limnologie tels que les nutriments. Pour atteindre cet objectif, nous avons déterminé la toxicité des mélanges sur plusieurs années de 14 herbicides régulièrement détectés dans le lac, en utilisant les modèles CA et RA avec les courbes de distribution de la sensibilité des espèces. Un gradient temporel de toxicité décroissant a pu être constaté de 2004 à 2009. Une analyse de redondance et de redondance partielle, a montré que ce gradient explique une partie significative de la variation de la composition de la communauté phytoplanctonique, même après avoir enlevé l'effet de toutes les autres co-variables. De plus, certaines espèces révélées pour avoir été influencées, positivement ou négativement, par la diminution de la toxicité dans le lac au fil du temps, ont montré des comportements similaires dans des études en mésocosmes. On peut en conclure que la toxicité du mélange herbicide est l'un des paramètres clés pour expliquer les changements de phytoplancton dans le lac Léman. En conclusion, il existe diverses méthodes pour prédire le risque des mélanges de micropolluants sur les espèces aquatiques et celui-ci peut jouer un rôle dans le fonctionnement des écosystèmes. Toutefois, ces modèles ont bien sûr des limites et des hypothèses sous-jacentes qu'il est important de considérer lors de leur application, avant d'utiliser leurs résultats pour la gestion des risques environnementaux. - For several years now, the scientists as well as the society is concerned by the aquatic risk organic micropollutants may pose. Indeed, several researches have shown the toxic effects these substances may induce on organisms living in our lakes or rivers, especially when they are exposed to acute or chronic concentrations. However, most of the studies focused on the toxicity of single compounds, i.e. considered individually. The same also goes in the current European regulations concerning the risk assessment procedures for the environment of these substances. But aquatic organisms are typically exposed every day simultaneously to thousands of organic compounds. The toxic effects resulting of these "cocktails" cannot be neglected. The ecological risk assessment of mixtures of such compounds has therefore to be addressed by scientists in the most reliable and appropriate way. In the first part of this thesis, the procedures currently envisioned for the aquatic mixture risk assessment in European legislations are described. These methodologies are based on the mixture model of concentration addition and the use of the predicted no effect concentrations (PNEC) or effect concentrations (EC50) with assessment factors. These principal approaches were applied to two specific case studies, Lake Geneva and the River Rhône in Switzerland, including a discussion of the outcomes of such applications. These first level assessments showed that the mixture risks for these studied cases exceeded rapidly the critical value. This exceeding is generally due to two or three main substances. The proposed procedures allow therefore the identification of the most problematic substances for which management measures, such as a reduction of the entrance to the aquatic environment, should be envisioned. However, it was also showed that the risk levels associated with mixtures of compounds are not negligible, even without considering these main substances. Indeed, it is the sum of the substances that is problematic, which is more challenging in term of risk management. Moreover, a lack of reliability in the procedures was highlighted, which can lead to contradictory results in terms of risk. This result is linked to the inconsistency in the assessment factors applied in the different methods. In the second part of the thesis, the reliability of the more advanced procedures to predict the mixture effect to communities in the aquatic system were investigated. These established methodologies combine the model of concentration addition (CA) or response addition (RA) with species sensitivity distribution curves (SSD). Indeed, the mixture effect predictions were shown to be consistent only when the mixture models are applied on a single species, and not on several species simultaneously aggregated to SSDs. Hence, A more stringent procedure for mixture risk assessment is proposed, that would be to apply first the CA or RA models to each species separately and, in a second step, to combine the results to build an SSD for a mixture. Unfortunately, this methodology is not applicable in most cases, because it requires large data sets usually not available. Therefore, the differences between the two methodologies were studied with datasets created artificially to characterize the robustness of the traditional approach applying models on species sensitivity distribution. The results showed that the use of CA on SSD directly might lead to underestimations of the mixture concentration affecting 5% or 50% of species, especially when substances present a large standard deviation of the distribution from the sensitivity of the species. The application of RA can lead to over- or underestimates, depending mainly on the slope of the dose-response curves of the individual species. The potential underestimation with RA becomes important when the ratio between the EC50 and the EC10 for the dose-response curve of the species composing the SSD are smaller than 100. However, considering common real cases of ecotoxicity data for substances, the mixture risk calculated by the methodology applying mixture models directly on SSDs remains consistent and would rather slightly overestimate the risk. These results can be used as a theoretical validation of the currently applied methodology. Nevertheless, when assessing the risk of mixtures, one has to keep in mind this source of error with this classical methodology, especially when SSDs present a distribution of the data outside the range determined in this study Finally, in the last part of this thesis, we confronted the mixture effect predictions with biological changes observed in the environment. In this study, long-term monitoring of a European great lake, Lake Geneva, provides the opportunity to assess to what extent the predicted toxicity of herbicide mixtures explains the changes in the composition of the phytoplankton community next to other classical limnology parameters such as nutrients. To reach this goal, the gradient of the mixture toxicity of 14 herbicides regularly detected in the lake was calculated, using concentration addition and response addition models. A decreasing temporal gradient of toxicity was observed from 2004 to 2009. Redundancy analysis and partial redundancy analysis showed that this gradient explains a significant portion of the variation in phytoplankton community composition, even when having removed the effect of all other co-variables. Moreover, some species that were revealed to be influenced positively or negatively, by the decrease of toxicity in the lake over time, showed similar behaviors in mesocosms studies. It could be concluded that the herbicide mixture toxicity is one of the key parameters to explain phytoplankton changes in Lake Geneva. To conclude, different methods exist to predict the risk of mixture in the ecosystems. But their reliability varies depending on the underlying hypotheses. One should therefore carefully consider these hypotheses, as well as the limits of the approaches, before using the results for environmental risk management

Pre- and postsynaptic effects of SKF64139, a phenylethanolamine N-methyltransferase inhibitor, in conscious normotensive rats

We investigated in conscious normotensive rats the effect of SKF64139 (2 mg i.v.), a potent phenylethanolamine N-methyltransferase (PNMT) inhibitor, on blood pressure responses to norepinephrine (40, 80, and 160 ng i.v.); methoxamine (2.5, 5 and 10 micrograms i.v.), a directly active sympathomimetic agent that is not taken up by adrenergic nerves; and tyramine (20, 40, and 80 micrograms i.v.), an indirectly acting sympathomimetic amine. The pressor effect of norepinephrine was not changed by 2 mg of SKF64139, while those of methoxamine and tyramine were significantly reduced. The dose-response curve to exogenous norepinephrine was also evaluated following blockade of norepinephrine uptake in the nerve endings using 0.25 mg desipramine i.v. This dose of desipramine had no effect on blood pressure increase induced by methoxamine. In rats pretreated with the neuronal uptake inhibitor desipramine in a dose that did not affect alpha-adrenoceptors, SKF64139 significantly decreased the pressor responses to norepinephrine. Increasing the dose of SKF64139 to 8 mg i.v. resulted in a significant fall in base-line blood pressure and in a blunted blood pressure response to norepinephrine. These data demonstrate that in vivo the PNMT inhibitor SKF64139 blocks alpha-adrenoceptors and inhibits neuronal uptake. The alpha-adrenoceptor blocking properties of SKF65139 are masked by simultaneous blockade of norepinephrine uptake when agonists with affinity for the uptake system are used. These findings need to be taken into account when interpreting cardiovascular effects of the PNMT inhibitor SKF64139.

Acute creatine ingestion in human: consequences on serum creatine and creatinine concentrations.

The aim of the study was to explore the effect of an acute dose of creatine (Cr) ingestion on serum Cr and serum creatinine (Crn) concentrations. Sixteen healthy subjects ingested a single dose of Cr (20 g) followed by the measurement of serum Cr and Crn concentration for 3 h up to a maximum of 6 h (n=6). In response to Cr ingestion a large rise in serum Cr concentration was observed (by 50 folds) occurring approximately 2 1/2h after the ingestion (peak value of 2.17 +/- 0.66 mmol x l(-1)). We also found a moderate but significant rise in serum Crn concentration averaging 13 % after 3 h (peak value at 99.5 +/- 10.5 micromol x l(-1)). A dose response curve obtained in two case studies, in whom different doses of Cr were ingested (0, 2.5, 5, 10, 15, 20 g and 0, 10, 20, 30 g), showed that serum Cr concentration as well as the peak time increased linearly with Cr ingestion. In addition, acute Crn ingestion (5 g) resulted in a substantial increase in serum Crn concentration (by 10 folds) but led to a minor rise in serum Cr concentration (by 2 folds). These results suggest that when acute doses of Cr are ingested in humans, the degree of conversion of exogenous Cr to Crn in the stomach and the gut can be considered as negligible following the first 6 h of ingestion. However, further studies are required to explore the prolonged effect of Cr on Crn metabolism.

Dose-dependent acute and sustained renal effects of the endothelin receptor antagonist avosentan in healthy subjects.

The endothelin receptor antagonist avosentan may cause fluid overload at doses of 25 and 50 mg, but the actual mechanisms of this effect are unclear. We conducted a placebo-controlled study in 23 healthy subjects to assess the renal effects of avosentan and the dose dependency of these effects. Oral avosentan was administered once daily for 8 days at doses of 0.5, 1.5, 5, and 50 mg. The drug induced a dose-dependent median increase in body weight, most pronounced at 50 mg (0.8 kg on day 8). Avosentan did not affect renal hemodynamics or plasma electrolytes. A dose-dependent median reduction in the fractional renal excretion of sodium was found (up to 8.7% at avosentan 50 mg); this reduction was paralleled by a dose-related increase in proximal sodium reabsorption. It is suggested that avosentan dose-dependently induces sodium retention by the kidney, mainly through proximal tubular effects. The potential clinical benefits of avosentan should therefore be investigated at doses of <or= 5 mg.

A low-dose stimulation protocol using highly purified follicle-stimulating hormone can lead to high pregnancy rates in in vitro fertilization patients with polycystic ovaries who are at risk of a high ovarian response to gonadotropins.

OBJECTIVE: To study the benefits of a low-dose stimulation (LDS) protocol with purified urinary follicle-stimulating hormone in patients with polycystic ovaries who have presented previously with a very high ovarian response to a standard hMG stimulation. DESIGN: Cohort study. SETTING: Fertility center in a university hospital. PATIENT(S): Sixty-one patients involved in an IVF/ICSI program from January 1995 to December 1996. INTERVENTION(S): The patients were first stimulated with a standard protocol using hMG and presented with a very high ovarian response. These patients were then stimulated a second time using a low-dose protocol. Cryopreserved embryos were transferred in later artificial or natural cycles until to December 1999. MAIN OUTCOME MEASURE(S): Number of gonadotropin ampules; estradiol level on the day of ovulation induction; follicles, oocytes, and cryopreserved zygotes; fertilization, implantation, and pregnancy rates; and number of ovarian hyperstimulation syndromes (OHSS). RESULT(S): The number of ampules used, the estradiol level reached, and the number of oocytes obtained were significantly lower under the LDS than the standard protocol. High implantation (21.8%) and clinical pregnancy (38.4%) rates were obtained after LDS. The cumulated deliveries per cycle started and per patient were, respectively, 41.6% and 52.5%. Five patients suffered OHSS with the standard protocol, and none with the LDS. CONCLUSION(S): The LDS protocol offers a safe and efficient treatment for patients who present with echographic polycystic ovaries and are at risk of an excessive ovarian response to standard IVF stimulation protocols.

Saturable metabolism of continuous high-dose ifosfamide with mesna and GM-CSF: a pharmacokinetic study in advanced sarcoma patients. Swiss Group for Clinical Cancer Research (SAKK).

BACKGROUND: The aim of this study was to assess the pharmacology, toxicity and activity of high-dose ifosfamide mesna +/- GM-CSF administered by a five-day continuous infusion at a total ifosfamide dose of 12-18 g/m2 in adult patients with advanced sarcomas. PATIENTS AND METHODS: Between January 1991 and October 1992 32 patients with advanced or metastatic sarcoma were entered the study. Twenty-seven patients were pretreated including twenty-three with prior ifosfamide at less than 8 g/m2 total dose/cycle. In 25 patients (27 cycles) extensive pharmacokinetic analyses were performed. RESULTS: The area under the plasma concentration-time curve (AUC) for ifosfamide increased linearly with dose while the AUC's of the metabolites measured in plasma by thin-layer chromatography did not increase with dose, particularly that of the active metabolite isophosphoramide mustard. Furthermore the AUC of the inactive carboxymetabolite did not increase with dose. Interpatient variability of pharmacokinetic parameters was high. Dose-limiting toxicity was myelosuppression at 18 g/m2 total dose with grade 4 neutropenia in five of six patients and grade 4 thrombocytopenia in four of six patients. Therefore the maximum tolerated dose was considered to be 18 g/m2 total dose. There was one CR and eleven PR in twenty-nine evaluable patients (overall response rate 41%). CONCLUSION: Both the activation and inactivation pathways of ifosfamide are non-linear and saturable at high-doses although the pharmacokinetics of the parent drug itself are dose linear. Ifosfamide doses greater than 14-16 g/m2 per cycle appear to result in a relative decrease of the active metabolite isophosphoramide mustard. These data suggest a dose-dependent saturation or even inhibition of ifosfamide metabolism by increasing high dose ifosfamide and suggest the need for further metabolic studies.

Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial.

BACKGROUND: Three small trials suggest that intravenous immunoglobulin can affect biomarkers and symptoms of mild-to-moderate Alzheimer's disease. We tested the safety, effective dose, and infusion interval of intravenous immunoglobulin in such patients. METHODS: We did a multicentre, placebo-controlled phase 2 trial at seven sites in the USA and five in Germany. Participants with probable Alzheimer's disease aged 50-85 years were randomly assigned (by a computer-generated randomisation sequence, with block sizes of eight) to infusions every 4 weeks (0·2, 0·5, or 0·8 g intravenous immunoglobulin per kg bodyweight, or placebo) or infusions every 2 weeks (0·1, 0·25, or 0·4 g/kg, or placebo). Patients, caregivers, investigators assessing outcomes, and staff at imaging facilities and the clinical research organisation were masked to treatment allocation, but dispensing pharmacists, the statistician, and the person responsible for final PET analyses were not. Treatment was masked with opaque pouches and infusion lines. The primary endpoint was median area under the curve (AUC) of plasma amyloid β (Aβ)(1-40) between the last infusion and the final visit (2 weeks or 4 weeks depending on infusion interval) in the intention-to-treat population. The trial is registered at ClinicalTrials.gov (NCT00812565) and controlled-trials.com (ISRCTN64846759). FINDINGS: 89 patients were assessed for eligibility, of whom 58 were enrolled and 55 included in the primary analysis. Median AUC of plasma Aβ(1-40) was not significantly different for intravenous immunoglobulin compared with placebo for five of the six intervention groups (-18·0 [range -1347·0 to 1068·5] for 0·2 g/kg, -364·3 [-5834·5 to 1953·5] for 0·5 g/kg, and -351·8 [-1084·0 to 936·5] for 0·8 g/kg every 4 weeks vs -116·3 [-1379·0 to 5266·0] for placebo; and -13·8 [-1729·0 to 307·0] for 0·1 g/kg, and -32·5 [-1102·5 to 451·5] for 0·25 g/kg every 2 weeks vs 159·5 [51·5 to 303·0] for placebo; p>0·05 for all). The difference in median AUC of plasma Aβ(1-40) between the 0·4 g/kg every 2 weeks group (47·0 [range -341·0 to 72·5]) and the placebo group was significant (p=0·0216). 25 of 42 (60%) patients in the intervention group versus nine of 14 (64%) receiving placebo had an adverse event. Four of 42 (10%) patients in the intravenous immunoglobulin group versus four of 14 (29%) receiving placebo had a serious adverse event, including one stroke in the intervention group. INTERPRETATION: Intravenous immunoglobulin may have an acceptable safety profile. Our results did not accord with those from previous studies. Longer trials with greater power are needed to assess the cognitive and functional effects of intravenous immunoglobulin in patients with Alzheimer's disease.

Treatment of advanced soft-tissue sarcomas using a combined strategy of high-dose ifosfamide, high-dose doxorubicin and salvage therapies.

Having determined in a phase I study the maximum tolerated dose of high-dose ifosfamide combined with high-dose doxorubicin, we now report the long-term results of a phase II trial in advanced soft-tissue sarcomas. Forty-six patients with locally advanced or metastatic soft-tissue sarcomas were included, with age <60 years and all except one in good performance status (0 or 1). The chemotherapy treatment consisted of ifosfamide 10 g m(-2) (continuous infusion for 5 days), doxorubicin 30 mg m(-2) day(-1) x 3 (total dose 90 mg m(-2)), mesna and granulocyte-colony stimulating factor. Cycles were repeated every 21 days. A median of 4 (1-6) cycles per patient was administered. Twenty-two patients responded to therapy, including three complete responders and 19 partial responders for an overall response rate of 48% (95% CI: 33-63%). The response rate was not different between localised and metastatic diseases or between histological types, but was higher in grade 3 tumours. Median overall survival was 19 months. Salvage therapies (surgery and/or radiotherapy) were performed in 43% of patients and found to be the most significant predictor for favourable survival (exploratory multivariate analysis). Haematological toxicity was severe, including grade > or =3 neutropenia in 59%, thrombopenia in 39% and anaemia in 27% of cycles. Three patients experienced grade 3 neurotoxicity and one patient died of septic shock. This high-dose regimen is toxic but nonetheless feasible in multicentre settings in non elderly patients with good performance status. A high response rate was obtained. Prolonged survival was mainly a function of salvage therapies.

Review of therapeutic drug monitoring of anticancer drugs part one - Cytotoxics.

Most anticancer drugs are characterised by a steep dose-response relationship and narrow therapeutic window. Inter-individual pharmacokinetic (PK) variability is often substantial. The most relevant PK parameter for cytotoxic drugs is the area under the plasma concentration versus time curve (AUC). Thus it is somewhat surprising that therapeutic drug monitoring (TDM) is still uncommon for the majority of agents. Goals of the review were to assess the rationale for more widely used TDM of cytotoxics in oncology. There are several reasons why TDM has never been fully implemented into daily oncology practice. These include difficulties in establishing appropriate concentration target ranges, common use of combination chemotherapies for many tumour types, analytical challenges with prodrugs, intracellular compounds, the paucity of published data from pharmacological trials and 'Day1=Day21' administration schedules. There are some specific situations for which these limitations are overcome, including high dose methotrexate, 5-fluorouracil infusion, mitotane and some high dose chemotherapy regimens. TDM in paediatric oncology represents an important challenge. Established TDM approaches includes the widely used anticancer agents carboplatin, busulfan and methotrexate, with 13-cis-retinoic acid also recently of interest. Considerable effort should be made to better define concentration-effect relationships and to utilise tools such as population PK/PD models and comparative randomised trials of classic dosing versus pharmacokinetically guided adaptive dosing. There is an important heterogeneity among clinical practices and a strong need to promote TDM guidelines among the oncological community.

A peripheral dose calculation model for estimating second cancer risk after breast radiotherapy

AbstractBreast cancer is one of the most common cancers affecting one in eight women during their lives. Survival rates have increased steadily thanks to early diagnosis with mammography screening and more efficient treatment strategies. Post-operative radiation therapy is a standard of care in the management of breast cancer and has been shown to reduce efficiently both local recurrence rate and breast cancer mortality. Radiation therapy is however associated with some late effects for long-term survivors. Radiation-induced secondary cancer is a relatively rare but severe late effect of radiation therapy. Currently, radiotherapy plans are essentially optimized to maximize tumor control and minimize late deterministic effects (tissue reactions) that are mainly associated with high doses (» 1 Gy). With improved cure rates and new radiation therapy technologies, it is also important to evaluate and minimize secondary cancer risks for different treatment techniques. This is a particularly challenging task due to the large uncertainties in the dose-response relationship.In contrast with late deterministic effects, secondary cancers may be associated with much lower doses and therefore out-of-field doses (also called peripheral doses) that are typically inferior to 1 Gy need to be determined accurately. Out-of-field doses result from patient scatter and head scatter from the treatment unit. These doses are particularly challenging to compute and we characterized it by Monte Carlo (MC) calculation. A detailed MC model of the Siemens Primus linear accelerator has been thoroughly validated with measurements. We investigated the accuracy of such a model for retrospective dosimetry in epidemiological studies on secondary cancers. Considering that patients in such large studies could be treated on a variety of machines, we assessed the uncertainty in reconstructed peripheral dose due to the variability of peripheral dose among various linac geometries. For large open fields (> 10x10 cm2), the uncertainty would be less than 50%, but for small fields and wedged fields the uncertainty in reconstructed dose could rise up to a factor of 10. It was concluded that such a model could be used for conventional treatments using large open fields only.The MC model of the Siemens Primus linac was then used to compare out-of-field doses for different treatment techniques in a female whole-body CT-based phantom. Current techniques such as conformai wedged-based radiotherapy and hybrid IMRT were investigated and compared to older two-dimensional radiotherapy techniques. MC doses were also compared to those of a commercial Treatment Planning System (TPS). While the TPS is routinely used to determine the dose to the contralateral breast and the ipsilateral lung which are mostly out of the treatment fields, we have shown that these doses may be highly inaccurate depending on the treatment technique investigated. MC shows that hybrid IMRT is dosimetrically similar to three-dimensional wedge-based radiotherapy within the field, but offers substantially reduced doses to out-of-field healthy organs.Finally, many different approaches to risk estimations extracted from the literature were applied to the calculated MC dose distribution. Absolute risks varied substantially as did the ratio of risk between two treatment techniques, reflecting the large uncertainties involved with current risk models. Despite all these uncertainties, the hybrid IMRT investigated resulted in systematically lower cancer risks than any of the other treatment techniques. More epidemiological studies with accurate dosimetry are required in the future to construct robust risk models. In the meantime, any treatment strategy that reduces out-of-field doses to healthy organs should be investigated. Electron radiotherapy might offer interesting possibilities with this regard.RésuméLe cancer du sein affecte une femme sur huit au cours de sa vie. Grâce au dépistage précoce et à des thérapies de plus en plus efficaces, le taux de guérison a augmenté au cours du temps. La radiothérapie postopératoire joue un rôle important dans le traitement du cancer du sein en réduisant le taux de récidive et la mortalité. Malheureusement, la radiothérapie peut aussi induire des toxicités tardives chez les patients guéris. En particulier, les cancers secondaires radio-induits sont une complication rare mais sévère de la radiothérapie. En routine clinique, les plans de radiothérapie sont essentiellement optimisées pour un contrôle local le plus élevé possible tout en minimisant les réactions tissulaires tardives qui sont essentiellement associées avec des hautes doses (» 1 Gy). Toutefois, avec l'introduction de différentes nouvelles techniques et avec l'augmentation des taux de survie, il devient impératif d'évaluer et de minimiser les risques de cancer secondaire pour différentes techniques de traitement. Une telle évaluation du risque est une tâche ardue étant donné les nombreuses incertitudes liées à la relation dose-risque.Contrairement aux effets tissulaires, les cancers secondaires peuvent aussi être induits par des basses doses dans des organes qui se trouvent hors des champs d'irradiation. Ces organes reçoivent des doses périphériques typiquement inférieures à 1 Gy qui résultent du diffusé du patient et du diffusé de l'accélérateur. Ces doses sont difficiles à calculer précisément, mais les algorithmes Monte Carlo (MC) permettent de les estimer avec une bonne précision. Un modèle MC détaillé de l'accélérateur Primus de Siemens a été élaboré et validé avec des mesures. La précision de ce modèle a également été déterminée pour la reconstruction de dose en épidémiologie. Si on considère que les patients inclus dans de larges cohortes sont traités sur une variété de machines, l'incertitude dans la reconstruction de dose périphérique a été étudiée en fonction de la variabilité de la dose périphérique pour différents types d'accélérateurs. Pour de grands champs (> 10x10 cm ), l'incertitude est inférieure à 50%, mais pour de petits champs et des champs filtrés, l'incertitude de la dose peut monter jusqu'à un facteur 10. En conclusion, un tel modèle ne peut être utilisé que pour les traitements conventionnels utilisant des grands champs.Le modèle MC de l'accélérateur Primus a été utilisé ensuite pour déterminer la dose périphérique pour différentes techniques dans un fantôme corps entier basé sur des coupes CT d'une patiente. Les techniques actuelles utilisant des champs filtrés ou encore l'IMRT hybride ont été étudiées et comparées par rapport aux techniques plus anciennes. Les doses calculées par MC ont été comparées à celles obtenues d'un logiciel de planification commercial (TPS). Alors que le TPS est utilisé en routine pour déterminer la dose au sein contralatéral et au poumon ipsilatéral qui sont principalement hors des faisceaux, nous avons montré que ces doses peuvent être plus ou moins précises selon la technTque étudiée. Les calculs MC montrent que la technique IMRT est dosimétriquement équivalente à celle basée sur des champs filtrés à l'intérieur des champs de traitement, mais offre une réduction importante de la dose aux organes périphériques.Finalement différents modèles de risque ont été étudiés sur la base des distributions de dose calculées par MC. Les risques absolus et le rapport des risques entre deux techniques de traitement varient grandement, ce qui reflète les grandes incertitudes liées aux différents modèles de risque. Malgré ces incertitudes, on a pu montrer que la technique IMRT offrait une réduction du risque systématique par rapport aux autres techniques. En attendant des données épidémiologiques supplémentaires sur la relation dose-risque, toute technique offrant une réduction des doses périphériques aux organes sains mérite d'être étudiée. La radiothérapie avec des électrons offre à ce titre des possibilités intéressantes.